The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

A multiomic analysis led by the IrsiCaixa AIDS Research Institute has uncovered genetic and immune mechanisms in some ...

Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly ...

As groundbreaking studies continue to reshape the human immunodeficiency virus (HIV) landscape, emerging therapies and ...

Some people infected with HIV are teeming with virus, but don’t get sick. Their resistive powers probably come from a mix of ...

Fostemsavir plus optimized background therapy was associated with improvements in immune biomarkers among HTE patients with MDR HIV infection.

Among recipients with HIV, kidney transplantation from donors with HIV is noninferior to that from donors without HIV.

Progress has been made in HIV care. However, that doesn’t mean you don’t need a detailed plan for taking care of an ...

Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...

The national HIV prevalence was 16. 3% among adults aged 15 years and older, translating to an estimated 7. 4 million adults ...

Mental Health, CUNY SPH doctoral alum Dana Watnick and team sought to explore local understandings of depression and mental ...

The following is a summary of “Infectious disease events in people with HIV receiving kidney transplantation: Analysis of the ...